Overland Park, KS — ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Washington D.C.-based The Weinberg Group Inc. The Weinberg Group is a leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. “We are excited to welcome The Weinberg Group into the ProPharma Group and Linden families,” said Michael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners. “This acquisition further solidifies ProPharma Group’s position as a leading, globally integrated pharmaceutical services platform with world class regulatory affairs and compliance services. We are confident the combination will accelerate ProPharma Group’s growth and enhance its reputation as a value-added partner to its clients.”
For more than 35 years, The Weinberg Group has used scientific and regulatory acumen to provide FDA-focused regulatory and compliance services, supplying its clients with viable and efficient development pathways and compliance solutions. With this acquisition, ProPharma Group’s service offering will expand to include highly specialized, U.S. based pre-approval/pre-clinical regulatory services, effectively establishing a true, end-to-end solution for its clients across the globe. “ProPharma was a natural fit for us,” said Matthew Weinberg, The Weinberg Group’s CEO. “Given both of our leading positions in the marketplace, adding our science-based regulatory and compliance skills to that of ProPharma Group’s provides all of our clients the ability to develop their products with both global and local outcomes in mind.”
ProPharma Group, a leading provider of compliance services, continues to expand its global presence, now with more than 1,100 employees across United States, Canada, Europe, Japan, and Australia. The Weinberg Group, with its professional team of regulatory experts and science-driven approach, aligns perfectly with ProPharma Group’s portfolio of high-value services for life science companies. The Weinberg Group’s leadership team brings an abundance of industry knowledge and expertise that complements ProPharma Group’s. Dawn Sherman, ProPharma Group CEO, said, “by joining forces, ProPharma Group now has the full complement of life science consulting, medical information, pharmacovigilance, and regulatory affairs expertise to serve our clients around the world, wherever they need us, and at whatever point in the lifecycle of their products.”
ProPharma Group, a portfolio company of Linden Capital Partners, is an international, independent, single-source provider of comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and medical devices. ProPharma Group has more than 1,100 colleagues worldwide providing an unmatched variety of compliance related services including life science consulting, medical information, pharmacovigilance, and regulatory affairs.
The Weinberg Group is the world’s leading FDA consultancy headquartered in Washington, D.C. For over 35 years, the company has provided pharmaceutical, biotechnology, and medical device consulting services to companies of every size on every continent, supplying them with viable and efficient drug development pathways and compliance solutions. Founded in 1983, The Weinberg Group has helped countless companies with FDA, regulatory, quality and compliance, and company-related matters. The Weinberg Group has a track record of success when interacting with the FDA; it has achieved this reputation of excellence using its proprietary approach to the Agency that combines vast scientific knowledge with extensive regulatory expertise.
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on investing in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.
For more information, visit www.ProPharmaGroup.com.
###